Siemens Healthineers AG (OTCMKTS:SMMNY) Given Consensus Rating of “Buy” by Analysts

Siemens Healthineers AG (OTCMKTS:SMMNY) has been given a consensus rating of “Buy” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and three have issued a strong buy recommendation on the company.

SMMNY has been the topic of several research reports. Citigroup restated a “buy” rating on shares of Siemens Healthineers in a research note on Friday, January 23rd. Zacks Research raised Siemens Healthineers from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Deutsche Bank Aktiengesellschaft cut Siemens Healthineers from a “buy” rating to a “hold” rating in a research note on Thursday, December 4th. Sanford C. Bernstein raised shares of Siemens Healthineers to a “strong-buy” rating in a report on Tuesday, January 13th. Finally, Royal Bank Of Canada started coverage on shares of Siemens Healthineers in a research report on Wednesday, December 17th. They set a “moderate buy” rating for the company.

Siemens Healthineers Trading Down 0.8%

Siemens Healthineers stock opened at $21.02 on Thursday. The business’s 50 day simple moving average is $23.55 and its 200 day simple moving average is $25.47. Siemens Healthineers has a 12 month low of $20.39 and a 12 month high of $28.92.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.